| scholarly article | Q13442814 |
| P953 | full work available at URL | http://www.jimmunol.org/cgi/content/abstract/149/2/548 |
| P698 | PubMed publication ID | 1624802 |
| P2093 | author name string | Barr PJ | |
| Chang SP | |||
| Hui GS | |||
| Gibson HL | |||
| Lee-Ng CT | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| antibody | Q79460 | ||
| parasite growth | Q122674855 | ||
| P304 | page(s) | 548-555 | |
| P577 | publication date | 1992-07-01 | |
| 1992-07-15 | |||
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth | |
| P478 | volume | 149 |
| Q41942680 | A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies. |
| Q37264673 | A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies |
| Q33599911 | A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. |
| Q35463512 | A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. |
| Q35557563 | A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain |
| Q35546112 | Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria |
| Q36718654 | Anti-malarial IgG subclasses pattern and FcγRIIa (CD32) polymorphism among pregnancy-associated malaria in semi-immune Saudi women. |
| Q36368911 | Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. |
| Q36363426 | Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. |
| Q36380869 | Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies |
| Q35010158 | Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines |
| Q48006728 | Antibody and clinical responses in volunteers to immunization with malaria peptide-diptheria toxoid conjugates |
| Q36396844 | Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2. |
| Q37274832 | Approaches to malaria vaccine development using the retrospectroscope |
| Q39830868 | Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies |
| Q39085980 | Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts |
| Q35456892 | Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies |
| Q36411599 | Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection |
| Q34004267 | Characterization of conserved T- and B-cell epitopes in plasmodium falciparum major merozoite surface protein 1 |
| Q35194707 | Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran |
| Q37523989 | Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli |
| Q38849729 | Complement and Antibody-mediated Enhancement of Red Blood Cell Invasion and Growth of Malaria Parasites |
| Q35550770 | CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine |
| Q35486529 | Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys |
| Q36368017 | Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among Plasmodium vivax Korean isolates |
| Q36938795 | Heterologous expression of plasmodial proteins for structural studies and functional annotation |
| Q37426223 | Human leukocyte antigen class II alleles influence levels of antibodies to the plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1 |
| Q33866574 | Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum |
| Q35516848 | Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection |
| Q35557454 | Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge |
| Q34003987 | Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. |
| Q36437429 | Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. |
| Q37425845 | Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142). |
| Q33605280 | Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus |
| Q33613892 | In vitro growth-inhibitory activity and malaria risk in a cohort study in mali |
| Q39655089 | In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system |
| Q35504908 | Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection |
| Q34367020 | Insect cells are superior to Escherichia coli in producing malaria proteins inducing IgG targeting PfEMP1 on infected erythrocytes |
| Q36615170 | Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine |
| Q60959901 | KILchip v1.0: A Novel Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization |
| Q35505807 | Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. |
| Q34008262 | Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam |
| Q33998800 | Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea |
| Q34541366 | Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro |
| Q34154429 | Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-119) in Iranians exposed to unstable malaria transmission |
| Q33742070 | Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines |
| Q35867604 | Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory |
| Q35762375 | Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies |
| Q33356029 | Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses |
| Q36404193 | Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies |
| Q35383761 | Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum |
| Q28740432 | T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines |
| Q33558061 | The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites |
| Q40784993 | The use of baculoviruses as expression vectors |
| Q34003578 | Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys |
Search more.